reference/14183711

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/14183711

Outgoing Links

Predicate	Object
contentType	Journal Article
endingPage	15672
issn	1949-2553
issueIdentifier	21
pageRange	15658-15672
publicationName	Oncotarget
startingPage	15658
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_a1ebfe17b0713ecaf89801f0370c078d
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_c0ed422bb43f19254987cf945ae517d8 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_babcdc193cfb28d855bbf44507b4775d http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_b876aa60813e63deac41b4407410ab2f http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_fca73b6cef5d3df56e19b2d238cde805
bibliographicCitation	Iyengar M, O'Hayer P, Cole A, Sebastian T, Yang K, Coffman L, Buckanovich RJ. CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer. Oncotarget. 2018 Mar 20;9(21):15658–72. PMID: 29644000; PMCID: PMC5884655.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2785e365737d997e69baa43e57016ab9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_99b75b13e6db83db3a55c96f758e203e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_733758a6855c2996913fa687da8d1b7d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7a8194ffad23368e4c46ffbead157719 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a512a76c80d481dd96c3fb7b36de4e6f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c363e945caf10cf2515df0cd2453343c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f1ff154e4bc056dbc689ec9539c1972d
date	2018-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.18632/oncotarget.24585 https://pubmed.ncbi.nlm.nih.gov/29644000 https://pubmed.ncbi.nlm.nih.gov/PMC5884655
isPartOf	https://portal.issn.org/resource/ISSN/1949-2553 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/37803
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID44631912 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8752 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_c343e6a7c6ed1f53a79a52a5af338d66 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23939 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5702198 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_848ea8bb1121ee393ad72ae0d412d8d2 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607

Total number of triples: 38.